Medtide Launches HK$514m IPO at Top of Range—U.S./China Expansion to Propel Peptide CDMO #3 in High-Growth GLP-1 Market

1. IPO Details Purpose of IPOMedtide plans to raise up to HKD 514 million (~USD 65.5 million), with proceeds allocated as follows: 76.4% for new peptide and oligonucleotide production facilities in the U.S. and China (including a...